Navigation Links
NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil®
Date:6/5/2011

tment with PLD represent a very high unmet medical need as there are currently no good treatment options available for these women.  These results demonstrate that NKTR-102 holds great therapeutic potential for women battling ovarian cancer.  We look forward to the continued late-stage development of NKTR-102." 

NKTR-102 was generally well tolerated in the subset of women with prior PLD treatment, particularly in the q21 dose schedule.  The most common Grade 3 and 4 side effects were diarrhea, hypokalemia, and nausea, with most side effects being Grade 3 in severity. [Table 3.]

NKTR-102 Phase 2 Data Presentation in Ovarian Cancer

  • The role of NKTR-102 in women with platinum resistant/refractory ovarian cancer and failure on pegylated liposomal doxorubicin (PLD).
    Abstract #5047, Poster Board #15C
    General Poster Session:  Gynecologic Cancer
    Session Date and Time:  Sunday, June 5, 2011, 8:00 AM – 12:00 PM, Central Time
    Location:  Hall A

  • The NKTR-102 Phase 2 Study was an international, multicenter, open-label, randomized, two-stage study to evaluate NKTR-102 when given either on a q14d or q21d regimen in women with platinum-resistant/refractory disease to any line of platinum-based chemotherapy (platinum-free interval <6 months).  46 percent (33/71) of the women in the study had failed prior treatment with PLD.  Median lines of prior therapy for this subpopulation of women enrolled in the study were 4.  The primary endpoint of the study was objective response rate (based on RECIST and GCIG response criteria).  Secondary endpoints were safety, progression-free survival and overall survival.  TABLE 1. Patient Demographics: Prior Therapies in Subpopulation Receiving Prior Treatment with PLDNKTR-102

    145 mg/m2 q14d

    (N=16)

    NKTR-102

    145 mg/m2 q21d

    (N=17)

    Total (N=33)Prior Lines of Therapy (median)


    '/>"/>
    SOURCE Nektar Therapeutics
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting
    2. Nektar Announces New Phase 2 Data for NKTR-102 to Be Presented at 2011 ASCO Annual Meeting
    3. FDA Grants Orphan Drug Designation for Nektars Investigational Drug, NKTR-102, for Treatment of Women with Ovarian Cancer
    4. NKTR-102 Demonstrates Significant Efficacy as Single-Agent in Second- or Third-Line Treatment in Metastatic Breast Cancer Patients
    5. NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress
    6. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
    7. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
    8. Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings
    9. Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting
    10. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
    11. NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/31/2015)... July 31, 2015 More than 1,500 substance ... will convene in Indianapolis Aug. ... 2015 Mid-Year Training Institute . The week-long training, held ... address one of our nation,s biggest public health challenges ... Training Institute is a one-of-a-kind intensive training opportunity, offering ...
    (Date:7/31/2015)... , July 31, 2015 The Physician-Patient ... release on July 28, 2015, "Surviving Your Hospital ... Fundraising for Patient Safety." A sentence ... should read: "PPAHS is a member ... on Opioids. For more information on the National Coalition ...
    (Date:7/31/2015)... , July 31, 2015  Xcelience, a contract ... it has made a structured cash investment in ... specializing in milling, micronization and powder size classification ... grow Powdersize,s business while simultaneously adding a complete ... portfolio of capabilities. "As we ...
    Breaking Medicine Technology:Community Leaders From Across The Country Head To Indianapolis For CADCA 2015 Mid-Year Training Institute Aug. 2-6 2Xcelience Makes Structured Cash Investment in Powdersize 2Xcelience Makes Structured Cash Investment in Powdersize 3
    ... CARLOS, Calif., Sept. 21 NeurogesX, Inc.,(Nasdaq: ... enrollment in study,C119, a second Phase 3 clinical ... treatment of painful HIV-distal sensory polyneuropathy,(HIV-DSP). NGX-4010 is ... Previously completed Phase 3 trials demonstrated that a,single, ...
    ... the American Journal of Nephrology -, DEERFIELD, Ill., ... its Phase III data on VAPRISOL was published in,the ... this study,VAPRISOL showed a significant increase in serum sodium ... that,occurs when the body,s sodium level falls below normal. ...
    Cached Medicine Technology:NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy 2NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy 3NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy 4Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia 2Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia 3Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia 4Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia 5
    (Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... Ticket Down is a reputable source of ... the MGM Grand Garden Arena. Fans of every genre of music will have an ... 18th, the first day of the festival, the following artists will perform: Sam Smith, ...
    (Date:7/31/2015)... Chicago, IL (PRWEB) , ... July 31, 2015 , ... ... which is currently going on in Chicago at Grant Park. The festival ... every corner of North America to Chicago for the annual Lollapalooza. This unique ...
    (Date:7/31/2015)... ... , ... The 2nd annual Ride to Fight On will start and end ... The Ride to Fight On is a cycling fundraiser that benefits the West Cancer ... and The University of Tennessee Health Science Center. A health and wellness festival featuring ...
    (Date:7/31/2015)... ... July 31, 2015 , ... Facebook, Twitter, Linkedin and ... their social media profiles to better connect with the public. The agency website ... information, share insights and opinions. The Rally Insurance Group, Inc.’s pledge to provide ...
    (Date:7/31/2015)... ... ... According to the article published July 27 on My News LA, a fire ... by the city’s fire department before it caused major damage throughout the building. The article ... and it was a fire alarm system that tipped off fire fighters so they could ...
    Breaking Medicine News(10 mins):Health News:Cheap 2015 iHeartRadio Music Festival Tickets in Las Vegas at MGM Grand Garden Arena: Ticket Down Slashes Ticket Prices on the iHeart Radio Music Festival in Vegas 2Health News:Cheap 2015 iHeartRadio Music Festival Tickets in Las Vegas at MGM Grand Garden Arena: Ticket Down Slashes Ticket Prices on the iHeart Radio Music Festival in Vegas 3Health News:Cheap 2015 Lollapalooza Tickets: Ticket Down Slashes Ticket Prices on Lollapalooza Tickets at Grant Park in Chicago for Saturday, August 1st and Sunday, August 2nd 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 3Health News:Rally Insurance Group, Inc. Connects to Customers Through Re-branded Social Media Profiles 2Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 2Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 3
    ... to $16.9 Million ... Company Raises ... ATS Medical, Inc.,(Nasdaq: ATSI ), manufacturer and marketer of state-of-the-art ... ended June 28, 2008. Revenue for the quarter was $16.9,million, up ...
    ... LOS ALTOS, Calif., Aug. 4 InteKrin Therapeutics, ... development of,products for diabetes, metabolism and obesity today ... Series C venture financing for $18.25,million. The financing ... CA and,Managing Director David Lowe Ph.D. of Skyline ...
    ... Susan Reichle, the U.S.,Agency for International Development,s deputy ... The promotion took place this morning after,Henrietta Fore, ... a,brief ceremony., "Susan,s appreciation for and skill ... well in her new position," said Fore. "Partnerships ...
    ... to doubled chance of weight gain, study finds , , MONDAY, ... not spending enough time in rapid eye movement (REM) sleep ... new U.S. study. , For three consecutive nights, researchers assessed ... They looked at total sleep time, time spent in REM, ...
    ... Anthem Care Comparison Tool Gives Anthem Members in ... Costs Associated with Medical Procedures, DENVER, Aug. ... in,Colorado announced today the launch of its industry-leading ... access to Anthem,Care Comparison, an online tool that ...
    ... NEW YORK (August 4, 2008) -- The 1st World ... bring together leading experts in diabetes, endocrinology, surgery and ... novel interventional therapies in the treatment of type 2 ... this emerging approach to diabetes and its implications for ...
    Cached Medicine News:Health News:ATS Medical Announces Second Quarter Results 2Health News:ATS Medical Announces Second Quarter Results 3Health News:ATS Medical Announces Second Quarter Results 4Health News:ATS Medical Announces Second Quarter Results 5Health News:ATS Medical Announces Second Quarter Results 6Health News:ATS Medical Announces Second Quarter Results 7Health News:ATS Medical Announces Second Quarter Results 8Health News:ATS Medical Announces Second Quarter Results 9Health News:ATS Medical Announces Second Quarter Results 10Health News:InteKrin Therapeutics Announces $20 Million Series C Financing 2Health News:Kids Who Sleep Poorly at Risk for Being Overweight 2Health News:Anthem Blue Cross and Blue Shield in Colorado Introduces Industry Leading and Comprehensive Transparency Initiative to Colorado 2Health News:Anthem Blue Cross and Blue Shield in Colorado Introduces Industry Leading and Comprehensive Transparency Initiative to Colorado 3Health News:1st World Congress On Interventional Therapies for Type 2 Diabetes 2Health News:1st World Congress On Interventional Therapies for Type 2 Diabetes 3Health News:1st World Congress On Interventional Therapies for Type 2 Diabetes 4
    ... ODEI750D cameras are a new generation of flexible ... digital and video imaging. Images are captured by ... both video and digital formats. Video signals include ... are sent to the PC as uncompressed TIFF ...
    Bench Top Vertical Airflow Cabinets Production Protection...
    Bench Top Horizontal (clean bench) Airflow Cabinet...
    ... This sealed isolation chamber provides a ... repackaging sterile pharmaceuticals, in accord with ... Class 100 (ISO 5) cleanliness conditions ... antechamber, IV rod and tilt-up front ...
    Medicine Products: